Evidence map›Paper›PMID 32740768›Full record

ReviewCurrent neurology and neuroscience reports2020

Infusion Therapies for Parkinson's Disease.

Neha Prakash, Tanya Simuni

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current neurology and neuroscience reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Current and novel infusion therapies for patients with Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2023
    Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Neha PrakashParkinson's Disease and Movement Disorders Center, Department of Neurology, University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, CT, 06030, USA. prakash@uchc.edu.ORCID 0000-0003-1726-1517
Tanya SimuniParkinson's Disease and Movement Disorders Center, Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Northwestern University · USUniversity of Connecticut · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewAdvanced Parkinson's disease (APD) is marked by significant motor and non-motor complications affecting the patient's quality of life. Optimization of standard oral therapies (SOT) at some point fails to provide adequate relief. Among the available device-aided therapies, infusion therapies (IT) work on the rationale that continuous striatal dopaminergic stimulation can significantly reduce the motor fluctuations and smoothen the treatment response. This review serves to familiarize readers with available IT for APD with a focus on motor and non-motor effects, and safety. RECENT

findingsSeveral recent longitudinal studies have demonstrated a reduction in OFF and an equivalent increase in ON time with the use of levodopa-carbidopa intestinal gel infusion (LCIG). Additionally, the benefit is noted on dyskinesia and non-motor symptoms. Similarly, backed by long-term clinical experience and open-label studies, a recent double-blind trial validates the efficacy of continuous subcutaneous apomorphine infusion (CSAI). Both IT are accompanied by a high rate of mild to moderate adverse events (AE) that can influence patient selection and clinical utility. While device and procedure-related AE are common for LCIG, infusion site reactions dominate the CSAI AE. IT are a viable and superior alternative for APD over SOT. Both therapies provide meaningful improvement of the motor fluctuations with a positive impact on the quality of life.

Indexed as

Parkinson DiseaseAntiparkinson AgentsGelsHumansLevodopaLongitudinal StudiesQuality of LifeAntiparkinson AgentsGelsLevodopaAdvanced therapyApomorphine infusionInfusion therapyLevodopa-carbidopa infusionParkinson’s disease

Identifiers

PMID32740768
OpenAlexW3046435081

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.